Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)

Ginsenosides have offered a wide array of beneficial roles in the pharmacological regulation of hepatic metabolic syndromes, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and obesity. Of the numerous ginsenosides, Rg3 has been widely investigated, but the...

Full description

Bibliographic Details
Main Authors: Jin Ha Lee, Ji Young Oh, Soo Hyun Kim, In Jeong Oh, Yong-ho Lee, Keun Woo Lee, Woong Hee Lee, Jeong-Hwan Kim
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Biomolecules
Subjects:
ginsenosides
gypenoside LXXV
drug discovery
liver fibrosis
nonalcoholic steatohepatitis (NASH)
hepatic stellate cells
Online Access:https://www.mdpi.com/2218-273X/10/10/1426

Similar Items

Similar Items